Jimini Health launches with $8M for AI-assisted therapynews2024-11-19T11:00:57+00:00November 19th, 2024|Endpoints News|
Biogen, UCB detail response rates in Phase 3 lupus trial after surprising successnews2024-11-19T06:00:35+00:00November 19th, 2024|Endpoints News|
Vir, Bluejay invigorate hepatitis D space with new datanews2024-11-19T02:35:51+00:00November 19th, 2024|Endpoints News|
Rocket shares promising long-term results from rare heart disease gene therapy in small studynews2024-11-18T20:31:08+00:00November 18th, 2024|Endpoints News|
Neurogene patient had life-threatening side effect in Rett syndrome studynews2024-11-18T19:55:48+00:00November 18th, 2024|Endpoints News|
Syndax’s Revuforj wins FDA approval in aggressive form of leukemianews2024-11-18T19:37:56+00:00November 18th, 2024|Endpoints News|
CSL Behring will close California office as part of shrinking ex vivo worknews2024-11-18T19:34:37+00:00November 18th, 2024|Endpoints News|
FDA offers more guidance on developing cell and gene therapiesnews2024-11-18T19:21:10+00:00November 18th, 2024|Endpoints News|
Regenxbio shares first data showing Duchenne gene therapy improves muscle functionnews2024-11-18T16:24:37+00:00November 18th, 2024|Endpoints News|
A rare neurological disease is Sage’s last, best hope after failures in depressionnews2024-11-18T16:22:00+00:00November 18th, 2024|Endpoints News|
